Sweden
· Delayed Price · Currency is SEK Coegin Pharma AB Company Description
Coegin Pharma AB, a biotechnology company, engages in developing peptide-based products for hair growth and skin pigmentation in Sweden.
The company develops Follicopeptide, a peptide designed to enhance hair growth; and NPP-4, a natural pigmentation peptide 4 works by facilitating the transport of melanin to the skin, mimicking the natural process that occurs during sun exposure or tanning beds.
It is also developing FOL026, a drug candidate which is in preclinical trial for the treatment of myocardial infarction; AVX420, a drug candidate which is in preclinical trial for the treatment of leukemia; and AVX001, a drug candidate which is in phase 2 clinical development to treat both actinic keratosis and basal cell carcinoma.
Coegin Pharma AB was founded in 2005 and is based in Lund, Sweden.
| Country | Sweden |
| Founded | 2005 |
| Industry | Pharmaceutical Preparations |
| Employees | 2 |
| CEO | Jens Eriksson |
Contact Details
Address: Medicon Village Lund, 223 81 Sweden | |
| Phone | 46 72 221 24 21 |
| Website | coeginpharma.com |
Stock Details
| Ticker Symbol | COEGIN |
| Exchange | Nordic Growth Market |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jens Eriksson | Chief Executive Officer |
| Lars Rasmussen | Chief Financial Officer |